Highlights of This Issue 3999

SPECIAL FEATURES

CCR Translations

4001 How to Develop Treatments for Biologically Heterogeneous "Diseases" Richard M. Simon See article p. 4004

Statistics in Clinical Cancer Research

4004 Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819 Mary W. Redman, John J. Crowley, Roy S. Herbst, Fred R. Hirsch, and David R. Gandara See commentary p. 4001

Molecular Pathways

4013 Molecular Pathways: Targeting Phosphoinositide 3-Kinase p110-Delta in Chronic Lymphocytic Leukemia Sarah E.M. Herman and Amy J. Johnson

4019 Molecular Pathways: Involving Microenvironment Damage Responses in Cancer Therapy Resistance Yu Sun and Peter S. Nelson

HUMAN CANCER BIOLOGY

4026 Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma Katja Harbst, Johan Staa, Martin Lauss, Anna Karlsson, Anna Masback, Iva Johansson, Pär-Ola Bendahl, Johan Vallon-Christersson, Therese Törnqvist, Henrik Ekedahl, Jürgen Geisler, Markus Höglund, Mattias Ringnér, Lotta Lundgren, Karin Jirstrom, Hakan Olsson, Christian Ingvar, Åke Borg, Hensin Tsao, and Göran Jonsson


4048 EZH2-Regulated DAB2IP Is a Medulloblastoma Tumor Suppressor and a Positive Marker for Survival Michiel Smits, Sjoerd van Rijn, Esther Hullemann, Dennis Biesmans, Danniël G. van Vuuren, Marcel Kool, Christine Haberler, Eleonora Aronica, W. Peter Vandertop, David P. Noske, and Thomas Wörzinger

4059 Overexpression of GOLPH3 Promotes Proliferation and Tumorigenicity in Breast Cancer via Suppression of the FOXO1 Transcription Factor Zhaolei Zeng, Huanxin Lin, Xiaohui Zhao, Guanglin Liu, Xi Wang, Ruihua Xu, Kun Chen, Jun Li, and Libing Song

CANCER THERAPY: PRECLINICAL

4070 Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts Gaspar J. Kitange, Ann C. Mladek, Brett L. Carlson, Mark A. Schroeder, Jenny L. Pokorny, Ling Cen, Paul A. Decker, Wenting Wu, Gwen A. Lomberk, Shiv K. Gupta, Raul A. Urrutia, and Jann N. Sarkaria

4080 IGKV3 Proteins as Candidate "Off-the-Shelf" Vaccines for Kappa-Light Chain–Restricted B-Cell Non-Hodgkin Lymphomas Debora Martorelli, Massimo Guidoboni, Valli De Re, Elena Muraro, Riccardo Turrini, Anna Merlo, Elisa Pasini, Laura Caggiari, Luca Romagnoli, Michele Spina, Roberta Mortarini, Daniela Gasparotto, Mario Mazzucato, Antonino Carbone, Antonio Rosato, Andrea Anichini, and Riccardo Dolcetti
IMAGING, DIAGNOSIS, PROGNOSIS

Progenitor-like Traits Contribute to Patient Survival and Prognosis in Oligodendrogial Tumors
Felicia Soo-Lee Ng, Tan Boon Toh, Esther Hui-Ling Ting, Geraldene Rong-Hui Koh, Edwin Sandanaraj, Mark Phong, Swee Seong Wong, Siew Hong Leong, Oi Lian Kon, Greg Tucker-Kellogg, Wai Hoe Ng, Ivan Ng, Carol Tang, and Beng Ti Ang

CANCER THERAPY: CLINICAL

A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors
David S. Hong, Daniel W. Bowles, Gerald S. Falchook, Wells A. Messersmith, Goldy C. George, Cindy L. O'Bryant, Alex C. H. Vo, Kevin Klucher, Roy S. Herbst, S. Gail Eckhardt, Scott Peterson, Diana F. Hausman, Bazelle Kurzrock, and Antonio Jimeno

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type
Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration
Ke Lin, Janet Adamson, Gillian G. Johnson, Anthony Carter, Melanie Oates, Rachel Wade, Sue Richards, David Gonzalez, Estella Matutes, Claire Dearden, David G. Oscier, Daniel Catovsky, and Andrew R. Pettitt

TP53 Genomic Status Regulates Sensitivity of Gastric Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep)
Lai Ling Cheng, Yoko Itahana, Zheng Deng Lei, Na-Yu Chia, Yonghui Wu, Yingnan Yu, Shen Li Zhang, Aye Aye Thike, Anuradha Pandey, Steve Rozen, Pieter Mathijs Voorhoeve, Qiang Yu, Puay Hoon Tan, Boom Huat Bay, Koji Itahana, and Patrick Tan

ABOUT THE COVER
The recently discovered recurrent ERG rearrangement is highly specific for prostate cancer. There are significant associations of ERG rearrangement in preoperative biopsies with pelvic lymph node metastasis for patients with prostate cancer. The fluorescence in situ hybridization image shows representative nuclei of a prostate cancer gland. One yellow/one green/one red in a nucleus represents abnormal signal patterns indicative of an ERG rearrangement. For details, please see the article by Gao and colleagues on page 4163 of this issue.

LETTERS TO THE EDITOR
Lifetime Cancer Risks of PTEN Mutation Carriers—Letter
Molly S. Daniels, Thereasa Rich, Scott Weissman, and Robert Pilarski

Lifetime Cancer Risks of PTEN Mutation Carriers—Response
Min-Han Tan, Jessica Mester, and Charis Eng

CORRECTIONS
Correction: New Strategies in Squamous Cell Carcinoma of the Lung: Identification of Tumor Drivers to Personalize Therapy

Correction: MicroRNA-148a Suppresses Tumor Cell Invasion and Metastasis by Downregulating ROCK1 in Gastric Cancer
Clinical Cancer Research

18 (15)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/18/15

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.